Vermont Pharmacist Prescribing Protocol – Tobacco Cessation Products

Background

A pharmacist may prescribe and dispense tobacco cessation products, approved by the Food and Drug Administration (FDA), in a manner consistent with a valid State protocol approved by the Commissioner of Health, after consultation with the Director of Professional Regulation and the Board of Pharmacy (BOP). 26 V.S.A. § 2023(b)(2)(A)(i).

Pharmacists who independently prescribe FDA-approved tobacco cessation products must follow this protocol. When prescribing per this protocol, the pharmacist is the prescriber-of-record.

General considerations

Prescribing FDA-approved tobacco cessation products under this protocol requires the pharmacist to:

- 1. Have training and education in that area sufficient to perform the duties involved
- 2. Document prescribing, including notifying the patient's primary care provider within 5 business days.
- 3. Keep a written copy of the protocol at each location from where prescriptions are issued for an FDA-approved tobacco cessation product
- 4. Provide a copy of the protocol available upon the request of an inspector.

Procedures

When an individual requests a prescription for FDA-approved tobacco cessation products, or when a pharmacist in his or her professional judgement offers to prescribe FDA-approved tobacco cessation products to an individual, the pharmacist shall perform the procedures outlined below:

- 1. Direct the patient to the counseling area, as required in <u>Administrative Rule 9.2</u>, to provide reasonable privacy
- 2. Determine if the patient has a primary care clinician and encourage them to seek routine primary care. If the patient does not have a primary care clinician, provide referral to patient for finding primary care services, such as <u>VT-211</u> or, for Medicaid beneficiaries, the <u>Vermont Medicaid Provider lookup</u>.
- 3. Patient assessment of readiness to guit
 - a. Ask about tobacco use at every encounter and assess a patient's readiness to quit.
 - b. For those interested and/or ready to quit, per current guidelines, common approaches for clinicians to assess patients' tobacco use include the following:
 - i. The 5 As: (1) Ask about tobacco use; (2) Advise to quit through clear, personalized messages; (3) Assess willingness to quit; (4) Assist in quitting; and (5) Arrange follow-up and support
 - ii. "Ask, Advise, Refer," which encourages clinicians to ask patients about tobacco use, advise them to quit, and refer them to telephone quit lines, other evidence-based cessation interventions, or both.
 - iii. Vital Sign: Treating smoking status as a vital sign and recording smoking status at every health visit are also frequently used to assess smoking status.
 - c. The pharmacist may offer to prescribe tobacco cessation medication to tobacco users and provide behavioral counseling and/or a referral to counseling.
- 4. Patient health screening for eligibility
 - Utilize and document a health screening procedure to identify appropriate candidates for treatment by the pharmacist, an example screening tool appears on page 4.
 Screening shall include:
 - 1. Current and past medical conditions

- 2. Allergies and hypersensitivities
- 3. Medication history
- 4. Determination of high-risk patients
- ii. The health screen may also include:
 - 1. social history
 - 2. family history
 - 3. current living environment

5. Determination and referral of high-risk patients

- i. The pharmacist shall assess for certain risk factors that may cause adverse events related to medication use and consult with or refer high-risk patients to a primary care provider, psychiatrist, or other provider, as appropriate.
- ii. For purposes of this protocol, the following patients are considered high-risk:
 - 1. Patient is pregnant or planning to become pregnant in the next six months
 - 2. Patient has cardiovascular disease and:
 - a. Has had a heart attack in the past 2 weeks
 - b. Has a history of arrhythmias or irregular heartbeat
 - c. Has unstable angina or experience chest pain with strenuous activity
 - 3. Patient has history of mental health disorder(s) and is not perceived to be stable.

6. Prescribing and dispensing to eligible patients

- a. Prescribing shall be performed in adherence to recommendations in appropriate, current clinical guidelines (see "Pharmacist Resources" on page 3)
- b. The pharmacist, in consultation with the patient, may prescribe and dispense any tobacco cessation product (alone or in combination) approved by the FDA.
- c. When a tobacco cessation product is dispensed under the protocol, the pharmacist shall provide necessary information about the product including but not limited to:
 - i. The name and description of the medicine
 - ii. The route, dosage form, dosage, route of administration, and recommended duration of drug therapy
 - iii. Special directions and precautions, as applicable
 - iv. Common adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance and the action required if they occur
 - v. Techniques for self-monitoring drug therapy
 - vi. Proper storage
 - vii. Prescription refill information
 - viii. Action to be taken in the event of a missed dose

7. Counseling

- Once the appropriate tobacco cessation product(s) has been determined, the pharmacist shall
 provide the patient with counseling on the administration, possible side effects, contraindications,
 and warnings associated with the therapy.
- b. The patient should be encouraged to ask questions and will be supplied with educational material on any therapies dispensed.
- c. Pharmacists shall provide appropriate behavioral counseling and/or refer the patient to other resources for assistance, including but not limited to the Vermont Tobacco Quitline (802Quits) at 1-800-QUITNOW.

8. Follow-up

- a. To reassess the appropriateness and/or continuation of therapy, pharmacists shall follow up with patients:
 - i. Within two weeks of initiating therapy
 - ii. After completion of a course of therapy

Authorized Drugs

Prescribing and dispensing done pursuant to this protocol is limited to FDA-approved tobacco cessation products.

Prescribing Records

The pharmacist must generate a written or electronic prescription for any FDA-approved tobacco cessation product pursuant to protocol-base prescribing. The prescription must include all the information required by Administrative Rule 10.1. The prescription must be processed in the same manner that any other prescription is processed, pursuant to the applicable statutes and rules for the dispensing of prescription drugs. The prescription shall be kept on file and maintained for a minimum of three years, as required by the rules of the Vermont BOP. Pharmacists are reminded to adhere to record-keeping requirements for prescriptions paid for by Medicare and Medicaid, which may differ from those required by BOP.

Pharmacist Resources – Clinical Practice Guidelines, Education and Training:

US Department of Health and Human Services, Public Health Services Task Force (USPSTF), <u>Interventions for Tobacco Smoking Cessation in Adults</u>, <u>Including Pregnant Persons</u> (updated January 2021)

Surgeon General's Report on Smoking Cessation 2020

<u>Clinical Practice Guideline for Treating Tobacco Use and Dependence. (see attached examples)</u>https://www.ahrq.gov/prevention/guidelines/tobacco/clinicians/update/index.html

Rx for Change (http://rxforchange.ucsf.edu). http://quitworks.makesmokinghistory.org/uploads/Intake%20Assess%20Guide%209.6.10.pdf

https://802quits.org/providers/

https://www.cdc.gov/tobacco/campaign/tips/partners/health/index.html?CDC AA refVal=https%3A%2F%2Fwww.cdc.gov%2Ftobacco%2Fcampaign%2Ftips%2Fpartners%2Fhealth%2Fpharmacist%2Findex.html (Includes resources such as Quit Line information, posters, videos, and 800-quit-now notepads, etc.)

Example Assessment Resources – kindly supplied by, and adapted from, the Indiana Pharmacists Association

- 1. Patient Intake Form (for health screening), page 4
- 2. Patient Treatment Plan Summary, page 7
- 3. Fourteen-Day Follow-up Form, page 9
- 4. Final Contact Form, page 11

Patient Intake Form

Date:	Time:	Pharmacist's name:	
Section 1: Patier	nt information		
Name (Last, Firs	t):	Date of birth:	Gender:
Primary phone number:		Home address:	
Insurance provid	der:		
BIN	PCN	Cardholder ID	Group number

PCP name: PCP phone number:

Section 2: Medical conditions

Current medical conditions:	Past medical conditions:
2	2
3	3
4	4
5	5

Section 3: High-risk screening

1	Pregnant or planning to become pregnant in the next 6 months?	No	Yes	
2	Heart attack in past 2 weeks?	No	Yes	IF YES, consult
3	History of arrhythmias or irregular heartbeat?	No	Yes	with or refer
4	Unstable angina or chest pain with strenuous activity?	No	Yes	patient to PCP.
5	History of mental health disorder and is perceived to not be stable?	No	Yes	

Section 4: Other history

- 1 Family history of tobacco use or tobacco-related disease
- 2 Other medical conditions

3	Current living environmen	nt	
4	Social history		
	tion 5: Medications and all rent medications:	ergies/hypersensitivities	
Alle	rgies/hypersensitivities:		
Sact	tion 6: Assess Tobacco Use	History	
	: Are you ready to set a qui : What types of tobacco / r	t date? N Y (if yes, record quit date below unde	er Documentation)
Ту		How much and how often (per day)?	How long used?
Cig	garettes		
E-c	cigarettes/JUUL/vaping		
	nokeless tobacco (dip, ew)		
Cig	gars or cigarillos		
Ot	her:		
ASK	: How many minutes aft	er you wake up do you have your first cigarette/to	bacco/nicotine?
ASK	: Any recent changes in	your tobacco/nicotine use?	

ASK: Did you call the tobacco quitline or participate in any other form of counseling? Y N

- If YES: How many times? When was last quit attempt? Longest quit attempt?

- If YES: What did you like, or not like, about it?

ASK: What quitting medicines have you tried in the past? Discuss effectiveness, withdrawal symptoms, how med was taken (daily and duration), overall experience (does it make sense to try it again?).

ASK: Main reasons for returning smoking/tobacco use? Anticipated challenges this time?

DOCUMENTATION

F READY TO SET QUIT DATE, complete the following and initial to the left of each requirement. Discuss medication options and select treatment Ask patient to choose a quit date (if using bupropion SR or varenicline, consider medication start date)			
Patient's planned quit date is:			
 Refer patient to Vermont's <u>802-Quits</u> (1-800-QUIT NOW) or another program: Document treatment plan Schedule follow-up appointment within 2 weeks of quit date: 			
Date and time:			
Circle one: In-person or Telephone ASK: Confirm preferred contact #			
Advise patient to follow-up with PCP Contact patient's PCP within 3 business days			

Patient Treatment Plan Summary

PCP name:	Telephone #:	Fax #:			
Dear Clinician: We have provided tobac	Dear Clinician: We have provided tobacco cessation treatment to your patient, as referenced below in Section 1.				
Please document this in his or her chart. We will meet with your patient again within the next two weeks (in person or via telephone, based on their preference), and again at the end of treatment and have advised him or her to follow-up with you. If you have questions, please contact us:					
Pharmacy name and address:					
Dispensing pharmacist's name:	Telepho	ne #:			
Section 1: Patient information					
Name (Last, First):	ı	Date of birth:			
Primary phone number:					
Section 2: Treatment plan					
■ <u>Medication 1</u> dispensed (name, stre	ength):				
Dosing:					
The following were discussed w	vith the patient:				
Proper use, duration of drug therapy, drug storage					
Techniques for self-monitoring of drug therapy					
What to do if a dose is missed					
Common adverse effec	Common adverse effects; how to avoid, and what to do if encountered				
Refill information					
■ Medication 2 dispensed (name, stre	ength) [X-out Med 2 if not applie	cable]			

Dosing:		
The following were discussed	with the patient:	
Proper use, duration	of drug therapy, drug storage	
Techniques for self-m	nonitoring of drug therapy	
What to do if a dose is	s missed	
Common adverse effe	ects; how to avoid, and what to do if encountered	
Refill information		
■ Behavioral counseling plan:		
Patient was advised to reduce	e caffeine intake (due to drug interaction with smoking)	
Select one or more of the follo	owing:	
Patient was advised to Patient was referred t	t to the Vermont's <u>802-Quits</u> (1-800-QUIT NOW) o call and enroll in the Vermont's 802-Quits program to a group or web-based program ng behavioral counseling at the pharmacy	
■ Date contacted patient's PCP:		
Date/time called or faxed:	If called, spoke with:	Initials:

Fourteen-Day Follow-Up Form

			ор . о	
D	Date: Tir	me: Pharmacist	's name:	
Se	Section 1: Patient informa	tion		
N	Name (Last, First):		Date of birth:	
Q	Quit date:			
Se	Section 2: Behavioral assis	tance		
- - -	Patient is participatin	th the <u>Vermont's 802-Quits</u> (1-800 g in a group or web-based prograehavioral counseling at the pharm	m	
[Does the patient feel he/s	she is getting sufficient help/supp	ort?	
١	What coping challenges h	ave they had since the quit date?	Cravings?	
Se	Section 3: Medication use			
_	- Cessation medication(s) (name, strength) currently bein	g used:	
_	- Date medication(s) wer	re initiated:		
_	- Are the medication(s) b	peing taken correctly? Yes No	[describe below]	
_	- Is the patient experience	cing any adverse effects due to th	e medication(s)? Yes	No [describe below]

- Are the patient's withdrawal symptoms being managed? Yes No [describe below]
- Plans for terminating the medication(s):

Section 4: Interventions
Describe what is working

Describe what is working as well as any changes that are recommended.

- 1 Medication regimen:
- 2 Behavioral assistance recommendations:

Section 5: Patient questions and concerns

Documentation

Complete the following and initial to the left of each requirement.

Discussed current medication use and modified regimen, if appropriate
Discussed behavioral assistance and modified recommendations, if appropriate
Documented ongoing treatment plan
Discussed plans for termination of medications
Notified patient that you will contact them at the <i>end</i> of their medication regimen
Date:
ASK: Confirm preferred contact #
Remind patient to follow-up with PCP at their next visit

Final Contact Form

This document should be completed by the pharmacist at the anticipated end of each patient's medication regimen.

The contact can be made in person or via telephone.

Date:	Time:	Pharmacist's name:	
Section 1: Patie	ent information		
Name (Last, Fir	st):	Date of birth:	
Quit date:			
Section 2: Cess	ation outcomes		
Patient ha	s successfully quit		
Patient qu	it but relapsed		
Duratio	on of quit attempt:		
Reason	(s) for relapse:		
Patient did	d not attempt to quit (៤	did not stay off of tobacco for more than 24 hours)	
Patient is	unable to be reached		
Date o	of contact attempt #1:		
Date o	of contact attempt #2:		
Section 3: Quit	ting strategies used		
<u>Vermont's</u>	heck all that apply] <u>8802-Quits</u> (1-800-QUI' web-based program I counseling at the pha		
Does the patie	ent feel he/she received	d sufficient help/support? (describe)	
Medication: [0	Check one]		
	ation was provided	falls are an	
	mpleted full duration on mpleted partial course		
	inpleted partial course	S. C.S.	

Challenges:		
— Did the patient experience any adverse effects due to the medication(s)?	No	Yes [If Yes, describe below]
— Were the patient's withdrawal symptoms adequately managed?	No	Yes [If No, describe below]
 Plans for terminating the medication(s): 		
— Plans for terminating the medication(s).		
Section 4: Future plans		
For tobacco-free patients: Prevent relapse		
For relapsed patients willing to try again: Initiate a new quit attempt		
For relapsed patients not willing to try again: Establish future resources fo	r whei	n they are ready
Notes:		
Section 5: Patient questions and concerns		
None noted		
Questions/concerns discussed: [Describe below]		

Vermont Pharmacist Prescribing Protocol – Tobacco Cessation Products

ΔP	PP	SO	٧F	n٠

Date: 12/28/2021

Commissioner, Vermont Department of Health

O.X. Date: 12/28/2021

Director, Office of Professional Regulation